scispace - formally typeset
Open AccessJournal ArticleDOI

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

Kimberly H. Allison, +21 more
- 20 Apr 2020 - 
- Vol. 38, Iss: 12, pp 1346-1366
TLDR
The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.
Abstract: 
PURPOSETo update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline.M...

read more

Citations
More filters
Journal ArticleDOI

Triple‑negative breast cancer therapy: Current and future perspectives (Review)

Kwang‑Ai Won, +1 more
- 01 Dec 2020 - 
TL;DR: Clinical trials in the management of TNBC are discussed as well as perspectives for potential future treatments and various new agents and combination strategies have been explored.
Journal ArticleDOI

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.

Elisa Agostinetto, +8 more
- 05 Jun 2021 - 
TL;DR: In this article, the distribution of PAM50 intrinsic subtypes within HER2-low BC subtypes according to hormonal receptor status (positive (HR+) and negative (HR−), and the impact of HER2low status on survival outcomes (progression free interval (PFI), disease-free interval (DFI), and overall survival (OS)).
Journal ArticleDOI

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era.

Angela Toss, +16 more
TL;DR: In this paper, the authors evaluated the consequences of a 2-month interruption of mammographic screening on breast cancer (BC) stage at diagnosis and upfront treatments in a region of Northern Italy highly affected by the severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) virus.
Journal ArticleDOI

Evolution of low HER2 expression between early and advanced-stage breast cancer.

Paolo Tarantino, +13 more
- 12 Jan 2022 - 
TL;DR: In this paper , the evolution of low human epidermal growth factor receptor 2 (HER2) expression during the course of disease is still poorly characterised, and controversial data exist on its prognostic implications.
Journal ArticleDOI

Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer.

Meng Jiang, +7 more
- 24 Feb 2021 - 
TL;DR: In this paper, the authors developed and validated a deep learning radiomic nomogram (DLRN) for pre-operatively assessing breast cancer pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) based on the pre- and post-treatment ultrasound.
References
More filters
Journal ArticleDOI

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

Joseph A. Sparano, +31 more
- 03 Jun 2018 - 
TL;DR: In this paper, the authors performed a prospective trial involving 10,273 women with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer.
Journal ArticleDOI

ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67

Vilppu J. Tuominen, +4 more
- 27 Jul 2010 - 
TL;DR: It is anticipated that free web applications, such as ImmunoRatio, will make the quantitative image analysis of ER, PR, and Ki-67 easy and straightforward in the diagnostic assessment of breast cancer specimens.
Journal ArticleDOI

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Harold J. Burstein, +11 more
- 10 Feb 2019 - 
TL;DR: The Panel noted that the benefits in absolute risk of reduction were modest and that, for lower-risk node-negative or limited node-positive cancers, an individualized approach to treatment duration that is based on considerations of risk reduction and tolerability was appropriate.
Journal ArticleDOI

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Roy R. L. Bastien, +33 more
- 04 Oct 2012 - 
TL;DR: The standard immunohistochemical panel for breast cancer (ER, PR, and HER2) does not adequately identify the PAM50 gene expression subtypes and single gene scoring for ESR1, PGR, and ERBB2 was more prognostic than the corresponding IHC markers as shown in a multivariate analysis.
Journal ArticleDOI

Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

D. Craig Allred, +11 more
- 05 Mar 2012 - 
TL;DR: Patients in NSABP B-24 with ER-positive DCIS receiving adjuvant tamoxifen after standard therapy showed significant reductions in subsequent breast cancer, and the use of adjuant tamoxIFen should be considered for patients with DCIS.
Related Papers (5)

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond, +31 more
- 01 Jun 2010 - 

Molecular portraits of human breast tumours

Charles M. Perou, +17 more
- 17 Aug 2000 - 

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 - 

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A. Goldhirsch, +57 more
- 01 Sep 2013 - 

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff, +19 more
- 01 Nov 2013 -